Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 370,773,952
  • Shares Outstanding, K 2,407,623
  • Annual Sales, $ 85,159 M
  • Annual Income, $ 35,153 M
  • EBIT $ 13,952 M
  • EBITDA $ 21,438 M
  • 60-Month Beta 0.53
  • Price/Sales 4.29
  • Price/Cash Flow 11.11
  • Price/Book 5.21

Options Overview Details

View History
  • Implied Volatility 15.43% ( -0.97%)
  • Historical Volatility 13.50%
  • IV Percentile 35%
  • IV Rank 29.10%
  • IV High 22.48% on 08/05/24
  • IV Low 12.53% on 05/09/24
  • Put/Call Vol Ratio 0.46
  • Today's Volume 27,587
  • Volume Avg (30-Day) 24,402
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 319,214
  • Open Int (30-Day) 348,159

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.99
  • Number of Estimates 7
  • High Estimate 2.10
  • Low Estimate 1.94
  • Prior Year 2.29
  • Growth Rate Est. (year over year) -13.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
150.76 +2.66%
on 11/14/24
166.00 -6.77%
on 10/23/24
-10.35 (-6.27%)
since 10/18/24
3-Month
150.76 +2.66%
on 11/14/24
168.85 -8.34%
on 09/04/24
-4.62 (-2.90%)
since 08/16/24
52-Week
143.13 +8.13%
on 04/18/24
168.85 -8.34%
on 09/04/24
+4.98 (+3.32%)
since 11/17/23

Most Recent Stories

More News
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside

ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about.

BAYRY : 5.3000 (-1.12%)
JNJ : 154.77 (+0.50%)
ORIC : 8.56 (+0.71%)
PFE : 24.86 (+0.24%)
3 Oversold Dividend Aristocrats Ready To Explode in 2025

These three companies all have one thing in common: they are all on sale.

KO : 61.86 (+0.19%)
JNJ : 154.77 (+0.50%)
ABBV : 166.28 (+0.78%)
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback

The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY announcing their results. AbbVie’s ABBV schizophrenia candidate, added from a recent...

BAYRY : 5.3000 (-1.12%)
AZN : 63.39 (+0.25%)
JNJ : 154.77 (+0.50%)
MRK : 96.56 (+0.26%)
ABBV : 166.28 (+0.78%)
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?

Stocks in these "safe" sectors are selling off as investors gravitate toward growth.

MO : 56.34 (+0.73%)
VHT : 260.78 (unch)
KO : 61.86 (+0.19%)
MRK : 96.56 (+0.26%)
JNJ : 154.77 (+0.50%)
UNH : 589.65 (-0.44%)
COMP : 6.19 (-2.06%)
COST : 919.51 (+1.37%)
VDC : 214.72 (+0.69%)
PG : 170.75 (+0.71%)
LLY : 727.20 (-2.55%)
VPU : 172.59 (+0.86%)
Bayer Q3 Earnings Miss Estimates, Nubeqa, Kerendia Boost Sales

Bayer AG BAYRY reported third-quarter 2024 core earnings of 7 cents per American Depositary Receipt (ADR), which missed the Zacks Consensus Estimate of 17 cents. The company reported earnings of 10 cents...

BAYRY : 5.3000 (-1.12%)
JNJ : 154.77 (+0.50%)
REGN : 762.00 (+0.69%)
Will ISRG Stock Continue Its Uptrend After Gaining 9.9% in a Month?

Shares of Intuitive Surgical ISRG have risen 9.9% in the past month against the Zacks Medical - Instruments industry’s decline of 1% and the broader Zacks Medical sector’s fall of 3.2%. The S&P 500...

JNJ : 154.77 (+0.50%)
MDT : 87.59 (+0.07%)
ISRG : 531.64 (+0.76%)
Are Wall Street Analysts Predicting Johnson & Johnson Stock Will Climb or Sink?

Johnson & Johnson has struggled to keep up with the broader market over the past year, and analysts are cautiously bullish on its future potential.

$SPX : 5,893.62 (+0.39%)
JNJ : 154.77 (+0.50%)
IHE : 66.60 (-0.49%)
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever

You'll also like these stocks for their track record of earnings growth.

ABT : 117.36 (+1.26%)
JNJ : 154.77 (+0.50%)
TEVA Stock Down 7% Despite Q3 Earnings & Sales Beat, Guidance Increase

Teva Pharmaceutical Industries TEVA reported third-quarter 2024 adjusted earnings of 69 cents per share, which beat the Zacks Consensus Estimate of 65 cents. Adjusted earnings rose 15% year over year.Revenues...

NVO : 99.81 (-1.90%)
JNJ : 154.77 (+0.50%)
TEVA : 16.49 (+0.37%)
ABBV : 166.28 (+0.78%)
Discover the 3 Best-Performing Biotech IPO Stocks of 2024

Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise.

UPB : 23.77 (-6.64%)
JNJ : 154.77 (+0.50%)
CGON : 33.21 (+0.96%)
AVBP : 27.05 (-0.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 158.96
2nd Resistance Point 157.14
1st Resistance Point 155.96
Last Price 154.77
1st Support Level 152.96
2nd Support Level 151.14
3rd Support Level 149.96

See More

52-Week High 168.85
Fibonacci 61.8% 159.02
Fibonacci 50% 155.99
Last Price 154.77
Fibonacci 38.2% 152.96
52-Week Low 143.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar